Protherics, AstraZeneca deal

PTI granted AZN a global license to develop and commercialize CytoFab, an anti- TNF alpha polyclonal antibody fragment that has completed Phase II testing to treat severe sepsis. AZN is responsible for clinical development, and PTI is responsible for manufacturing and supply of clinical trial material. AZN plans to start a Phase III trial in the U.S. and EU in 2007. ...